Anti Mesothelin  

Immunohistochemistry using Rockland's anti-mesothelin antibody to react with two epitopes on mesothelin in PEFF human mesothelioma tissue sections treated by antigen retrieval methods. Anti-mesothelin primary antibodies were used at 10 μg/mL to label these sections as follows: C, MAb MB; and D, MAb MN followed by goat anti-mouse IgG conjugated to horseradish peroxidase at 25 μg/mL in 1% BSA/PBS for 30 minutes. (magnification, ×200; bar, 50 μm). Reprinted with permission from Clin.Cancer Res. 11(16):5840-6.

SDS-PAGE of Mouse anti-Mesothelin Monoclonal Antibody. Lane 1: Non-Reduced Mouse anti-Mesothelin Monoclonal Antibody. Lane M: 3 μL OPAL Pre-stained Marker (p/n MB-210-0500). Lane 2: Reduced Mouse anti-Mesothelin Monoclonal Antibody. Load: 1 μg per lane. Predicted/Observed size: Non-reduced at 160 kDa; Reduced at 55, 25 kDa.

Western blotting using Rockland's anti-mesothelin antibody. Load: Mesothelin-Fc (lane 1, 100 ng; lane 2, 25 ng; lane 3, 6 ng; lane 4, 2 ng; and lane 5, 0.4 ng) and CD25-Fc (lane 6, 50 ng) Primary antibody: anti-mesothelin at 1mg/ml. Secondary Antibody: ALP goat anti-mouse IgG and BCIP/NBT substrate. Reprinted with permission from Clin.Cancer Res. 11(16):5840-6.

Flow Cytometry Results of Anti-Mesothelin (MOUSE) Monoclonal Antibody. The green histogram shows NCI-H226 cells and blue histogram shows MCF-7 cells. Both cell lines are stained with a 1:200 dilution Anti-Mesothelin (MOUSE) Monoclonal Antibody. The secondary antibody use was Anti-Mouse IgG (H&L) (GOAT) Antibody DyLight^TM 488 Conjugated (p/n 610-141-002, lot#43322) at the 1:400 dilution.

Cells were incubated with the indicated primary antibodies or isotope control antibodies, and appropriate secondary antibody (goat anti-mouse IgG, R-PE or goat anti-mouse, FITC). Results are shown as histogram plots for binding of primary antibody (black trace) or isotype control (gray trace). A431 cells are negative for both MSLN and CA125. A549 cells show low mesothelin expression (3.5×103？sites/cell) but highly express CA125. Fig3. PMID:？25118887

(A) Tumor cells present in ascites were evaluated by their positivity for the tumor differentiation antigen mesothelin by flow cytometry using mouse anti-mesothelin (p/n 200-301-A87) primary antibody followed by goat anti-mouse IgG PE labeled secondary antibody. Shaded histogram represents the binding of isotype control antibody and solid histograms represent the binding of anti-mesothelin antibody. (B) Reactivity of lymphocytes with autologous tumor cells was evaluated by measuring IFN-γ released in the supernatants of co-cultures of lymphocytes and tumor cells. (C) Flow cytometry analysis of PD-L1 expression on autologous tumor cells obtained from ascites of patient NCI-Meso29 grown in the presence (solid) or absence (shaded) of autologous lymphocytes cultured from ascites and 106？IU/mL IL-2. Fig 4. PMID:？27544053

MSLN immunohistochemistry in colon cancer tissue. (A) Case of tubular adenocarcinoma. Diffuse and luminal MSLN expression was detected. (B) Case of poorly differentiated adenocarcinoma exhibiting solid/sheet-like proliferation with undetectable MSLN expression. Left, low-power magnification; right, high-power magnification. Scale bar, 500 μm. MSLN, mesothelin. Fig 1. PMID:？32194667

Expression of MSLN in cultured colon cancer cells. MSLN was expressed in four of seven colon cancer cell lines with no association with sex. MSLN, mesothelin; F, female; M, male. Fig 3. PMID:？32194667